Table 1.

Summary of Efficacy Outcomes for Ruxolitinib 1.5% Cream BID vs Vehicle BID (if Applicable) at Week 8 in Phase I–III Studies

	IGA-TS (%)a	EASI-75 (%)b	NRS4 (%)c	% Reduction in EASI	% Reduction in Itch NRS
Phase I
Ruxolitinib 1.5% (n=41)	56.8	94.6	90.5	− 93.75	N/A
Phase II
Ruxolitinib 1.5% (n=50)	48.0*	N/A	N/A	− 78.5*	− 68.5**
Vehicle (n=52)	9.6	N/A	N/A	− 26.9	− 17.6
Phase III (TRuE-AD1)
Ruxolitinib 1.5% (n=253)	53.8**	62.1**	52.2**	− 77.2**	− 67.3**
Vehicle (n=126)	15.1	24.6	15.4	− 40.5	− 35.3
Phase III (TRuE-AD2)
Ruxolitinib 1.5% (n=228)	51.3**	61.8**	50.7**	− 74.7**	− 62.0**
Vehicle (n=118)	7.6	14.4	16.3	− 28.9	− 32.1

Notes: *p<0.001 vs vehicle, **p<0.0001 vs vehicle. ^aProportion of patients who achieved IGA treatment success, defined as IGA score of 0/1 with a ≥2-grade improvement from baseline, ^bProportion of patients with a ≥75% improvement in the Eczema Area and Severity Index, ^cProportion of patients with a ≥4-point improvement in the itch Numerical Rating Scale score.

Abbreviations: BID, twice daily; EASI, Eczema Area and Severity Index; IGA-TS, Investigator’s Global Assessment – Treatment Success; N/A, not applicable; NRS, Numerical Rating Scale; TRuE-AD1, Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1; TRuE-AD2, Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2.